CTLA4 and neoplasm: Immune checkpoint inhibitors (ICIs) are promising new immunotherapeutic drugs that reactivate T cells to kill tumor cells by the blocking programmed cell death protein 1/ligand 1 (PD-1/PD-L1) pathway or the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathway.